As expected, cisplatin, docetaxel, and paclitaxel were predicted to have greater efficacy in triple-negative breast cancer (TNBC), and lapatinib in the HER-2 amplified subtype, using cell lines from the training (Figure 1a) or validation (Figure 1b) datasets. Here, ERBB2 is linked to triple-negative breast carcinoma.